Elagolix + Placebo
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Uterine Fibroids
Conditions
Uterine Fibroids
Trial Timeline
Apr 12, 2019 → Apr 28, 2021
NCT ID
NCT03886220About Elagolix + Placebo
Elagolix + Placebo is a approved stage product being developed by AbbVie for Uterine Fibroids. The current trial status is completed. This product is registered under clinical trial identifier NCT03886220. Target conditions include Uterine Fibroids.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03951077 | Phase 2 | Completed |
| NCT03886220 | Approved | Completed |
| NCT00619866 | Phase 2 | Completed |
Competing Products
20 competing products in Uterine Fibroids